脑脊液腰大池引流对动脉瘤性蛛网膜下腔出血患者的有效性:更新的系统综述与Meta分析
该系统综述与Meta分析纳入14项研究共2473例动脉瘤性蛛网膜下腔出血患者,比较腰大池引流与非引流组。腰大池引流组症状性血管痉挛、继发性脑梗死及出院至1个月死亡率均较低,但6个月良好功能结局无显著差异。
要点
- 腰大池引流组症状性血管痉挛风险显著低于非引流组(RR 0.61,95%CI 0.48-0.77)。
- 腰大池引流组继发性脑梗死风险显著低于非引流组(RR 0.59,95%CI 0.45-0.79)。
- 出院至1个月死亡率腰大池引流组显著低于非引流组(RR 0.58,95%CI 0.41-0.82),6个月时差异不显著。
核心结论
- 对动脉瘤性蛛网膜下腔出血患者,腰大池引流与血管痉挛、继发性脑梗死及死亡率降低相关,且不增加不良事件风险。
研究设计与样本
- 系统检索Medline、Embase和Cochrane Central Register of Controlled Trials,纳入14项研究共2473例动脉瘤性蛛网膜下腔出血患者。
主要发现
- 腰大池引流组与非引流组相比,出院至1个月良好功能结局率无显著差异(RR 1.28,95%CI 0.64-2.58)。
- 腰大池引流组与非引流组相比,6个月良好功能结局率无显著差异(RR 1.12,95%CI 0.97-1.41)。
- 腰大池引流组症状性血管痉挛率低于非引流组(RR 0.61,95%CI 0.48-0.77)。
- 腰大池引流组继发性脑梗死率低于非引流组(RR 0.59,95%CI 0.45-0.79)。
- 腰大池引流组出院至1个月死亡率低于非引流组(RR 0.58,95%CI 0.41-0.82),6个月死亡率差异不显著(RR 0.70,95%CI 0.34-1.45);仅分析随机对照试验时6个月死亡率仍较低(RR 0.75,95%CI 0.58-0.99)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Cerebral vasospasm in patients after aneurysmal subarachnoid hemorrhage (aSAH) continues to be a major source of morbidity despite significant clinical and basic science research. The removal of blood and its degradation products from the subarachnoid space through prophylactic lumbar drainage (LD) is a favorable option. However, several studies have delivered conflicting conclusions on its efficacy after aSAH. METHODS: Systematic searches of Medline, Embase, and Cochrane Central Register of Controlled Trials were performed. The primary outcome was a good functional outcome (modified Rankin scale score, 0-2). Secondary outcomes included symptomatic vasospasm, secondary cerebral infarction, and mortality. RESULTS: A total of 14 studies reporting on 2473 patients with aSAH were included in the meta-analysis. Compared with the non-LD group, no significant differences were found in the rates of good functional outcomes in the LD group at discharge to 1 month (risk ratio [RR], 1.28; 95% confidence interval [CI], 0.64-2.58) or at 6 months (RR, 1.12; 95% CI, 0.97-1.41). These findings were consistent in the subgroup analyses of only randomized controlled trials or observational studies. LD was associated with lower rates of symptomatic vasospasm (RR, 0.61; 95% CI, 0.48-0.77), secondary cerebral infarction (RR, 0.59; 95% CI, 0.45-0.79), and mortality at discharge to 1 month (RR, 0.58; 95% CI, 0.41-0.82). The effect on mortality diminished at 6 months (RR, 0.70; 95% CI, 0.34-1.45). However, when analyzing only randomized controlled trials, the benefit of LD on lower rates of mortality continued even at 6 months (RR, 0.75; 95% CI, 0.58-0.99). CONCLUSIONS: For aSAH patients, the use of LD is associated with benefits in the rates of vasospasm, secondary cerebral infarctions, and mortality, without an increased risk of adverse events.
引用
- Lee KS, Chari A, Motiwala M, et al. Effectiveness of Cerebrospinal Fluid Lumbar Drainage Among Patients with Aneurysmal Subarachnoid Hemorrhage: An Updated Systematic Review and Meta-Analysis. World Neurosurg. 2024. PMID: 38246528. doi:10.1016/j.wneu.2024.01.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。